AG
GTHX

Aperio Group’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Aperio Group’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$358K Buy
19,890
+1,209
+6% +$18.1K ﹤0.01% 2109
2020
Q3 		$216K Buy
18,681
+3,632
+24% +$59.9K ﹤0.01% 2199
2020
Q2 		$365K Buy
15,049
+4,881
+48% +$80.7K ﹤0.01% 1935
2020
Q1 		$112K Buy
+10,168
New +$190K ﹤0.01% 2202
2019
Q3 		– Sell
-599
Closed -$18K – 2811
2019
Q2 		$18K Buy
+599
New +$12.6K ﹤0.01% 2704

Other funds holding GTHX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Aperio Group's GTHX Position: Q4 2020 in Review

Aperio Group increased its G1 Therapeutics, Inc. Common Stock (GTHX) stake by 6.5% in Q4 2020, buying an estimated $18.1K and bringing the position to 19,890 shares worth $358K. The position accounts for ﹤0.01% of the portfolio, ranked #2109.

Aperio Group first reported a position in GTHX in Q2 2019 and has held it in 5 quarters since. The position peaked at $365K in Q2 2020. 125 funds tracked by Wall St. Rank hold GTHX as of Q4 2020.

  • Aperio Group held 19,890 shares of G1 Therapeutics, Inc. Common Stock worth $358K as of Q4 2020.
  • Aperio Group bought 1,209 G1 Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $18.1K.
  • G1 Therapeutics, Inc. Common Stock made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #2109 holding.
  • Aperio Group first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2019 and has held it in 5 quarters since.
  • Aperio Group's G1 Therapeutics, Inc. Common Stock position peaked at $365K in Q2 2020.
  • 125 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.